Structure-activity relationship of indoline-2-carboxylic acid N-(substituted)phenylamide derivatives. 2010

Jae-Hwan Kwak, and Yoseob Kim, and Hyunjeong Park, and Jae-Yong Jang, and Keun Kuk Lee, and Wonhui Yi, and Jeong-Ah Kwak, and Song-Gyu Park, and Hwanmook Kim, and Kiho Lee, and Jong Soon Kang, and Sang-Bae Han, and Bang Yeon Hwang, and Jin Tae Hong, and Jae-Kyung Jung, and Youngsoo Kim, and Jungsook Cho, and Heesoon Lee
Department of Pharmacy, Chungbuk National University, Chungbuk, Republic of Korea.

Chroman derivatives exhibited potent inhibitory activity of NF-kappaB. For SAR, the chroman scaffold was modified with an indoline moiety. A series of indoline-2-carboxylic acid N-(substituted)phenylamide derivatives were synthesized to explore their inhibitory activities of NF-kappaB and they were also evaluated for cytotoxicity against various cancer cell lines. Since intermediates with Boc showed outstanding results, various substituents in place of the Boc group were introduced additionally and these compounds were also evaluated for SAR.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D002839 Chromans Benzopyrans saturated in the 2 and 3 positions. Dihydrobenzopyrans
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001596 Benzylamines Toluenes in which one hydrogen of the methyl group is substituted by an amino group. Permitted are any substituents on the benzene ring or the amino group. Phenylmethylamine,alpha-Aminotoluene,alpha Aminotoluene
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D016328 NF-kappa B Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA. Immunoglobulin Enhancer-Binding Protein,NF-kappa B Complex,Nuclear Factor kappa B,Transcription Factor NF-kB,kappa B Enhancer Binding Protein,Ig-EBP-1,NF-kB,NF-kappaB,Nuclear Factor-Kappab,Complex, NF-kappa B,Enhancer-Binding Protein, Immunoglobulin,Factor NF-kB, Transcription,Factor-Kappab, Nuclear,Ig EBP 1,Immunoglobulin Enhancer Binding Protein,NF kB,NF kappa B Complex,NF kappaB,NF-kB, Transcription Factor,Nuclear Factor Kappab,Transcription Factor NF kB
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Jae-Hwan Kwak, and Yoseob Kim, and Hyunjeong Park, and Jae-Yong Jang, and Keun Kuk Lee, and Wonhui Yi, and Jeong-Ah Kwak, and Song-Gyu Park, and Hwanmook Kim, and Kiho Lee, and Jong Soon Kang, and Sang-Bae Han, and Bang Yeon Hwang, and Jin Tae Hong, and Jae-Kyung Jung, and Youngsoo Kim, and Jungsook Cho, and Heesoon Lee
February 1977, Journal of pharmaceutical sciences,
Jae-Hwan Kwak, and Yoseob Kim, and Hyunjeong Park, and Jae-Yong Jang, and Keun Kuk Lee, and Wonhui Yi, and Jeong-Ah Kwak, and Song-Gyu Park, and Hwanmook Kim, and Kiho Lee, and Jong Soon Kang, and Sang-Bae Han, and Bang Yeon Hwang, and Jin Tae Hong, and Jae-Kyung Jung, and Youngsoo Kim, and Jungsook Cho, and Heesoon Lee
December 2007, Bioorganic & medicinal chemistry,
Jae-Hwan Kwak, and Yoseob Kim, and Hyunjeong Park, and Jae-Yong Jang, and Keun Kuk Lee, and Wonhui Yi, and Jeong-Ah Kwak, and Song-Gyu Park, and Hwanmook Kim, and Kiho Lee, and Jong Soon Kang, and Sang-Bae Han, and Bang Yeon Hwang, and Jin Tae Hong, and Jae-Kyung Jung, and Youngsoo Kim, and Jungsook Cho, and Heesoon Lee
July 2011, Archiv der Pharmazie,
Jae-Hwan Kwak, and Yoseob Kim, and Hyunjeong Park, and Jae-Yong Jang, and Keun Kuk Lee, and Wonhui Yi, and Jeong-Ah Kwak, and Song-Gyu Park, and Hwanmook Kim, and Kiho Lee, and Jong Soon Kang, and Sang-Bae Han, and Bang Yeon Hwang, and Jin Tae Hong, and Jae-Kyung Jung, and Youngsoo Kim, and Jungsook Cho, and Heesoon Lee
November 2003, Farmaco (Societa chimica italiana : 1989),
Jae-Hwan Kwak, and Yoseob Kim, and Hyunjeong Park, and Jae-Yong Jang, and Keun Kuk Lee, and Wonhui Yi, and Jeong-Ah Kwak, and Song-Gyu Park, and Hwanmook Kim, and Kiho Lee, and Jong Soon Kang, and Sang-Bae Han, and Bang Yeon Hwang, and Jin Tae Hong, and Jae-Kyung Jung, and Youngsoo Kim, and Jungsook Cho, and Heesoon Lee
May 2024, ChemSusChem,
Jae-Hwan Kwak, and Yoseob Kim, and Hyunjeong Park, and Jae-Yong Jang, and Keun Kuk Lee, and Wonhui Yi, and Jeong-Ah Kwak, and Song-Gyu Park, and Hwanmook Kim, and Kiho Lee, and Jong Soon Kang, and Sang-Bae Han, and Bang Yeon Hwang, and Jin Tae Hong, and Jae-Kyung Jung, and Youngsoo Kim, and Jungsook Cho, and Heesoon Lee
September 2011, Bioorganic & medicinal chemistry letters,
Jae-Hwan Kwak, and Yoseob Kim, and Hyunjeong Park, and Jae-Yong Jang, and Keun Kuk Lee, and Wonhui Yi, and Jeong-Ah Kwak, and Song-Gyu Park, and Hwanmook Kim, and Kiho Lee, and Jong Soon Kang, and Sang-Bae Han, and Bang Yeon Hwang, and Jin Tae Hong, and Jae-Kyung Jung, and Youngsoo Kim, and Jungsook Cho, and Heesoon Lee
February 2015, Organic & biomolecular chemistry,
Jae-Hwan Kwak, and Yoseob Kim, and Hyunjeong Park, and Jae-Yong Jang, and Keun Kuk Lee, and Wonhui Yi, and Jeong-Ah Kwak, and Song-Gyu Park, and Hwanmook Kim, and Kiho Lee, and Jong Soon Kang, and Sang-Bae Han, and Bang Yeon Hwang, and Jin Tae Hong, and Jae-Kyung Jung, and Youngsoo Kim, and Jungsook Cho, and Heesoon Lee
July 2002, Acta crystallographica. Section C, Crystal structure communications,
Jae-Hwan Kwak, and Yoseob Kim, and Hyunjeong Park, and Jae-Yong Jang, and Keun Kuk Lee, and Wonhui Yi, and Jeong-Ah Kwak, and Song-Gyu Park, and Hwanmook Kim, and Kiho Lee, and Jong Soon Kang, and Sang-Bae Han, and Bang Yeon Hwang, and Jin Tae Hong, and Jae-Kyung Jung, and Youngsoo Kim, and Jungsook Cho, and Heesoon Lee
January 1972, Archiv der Pharmazie,
Jae-Hwan Kwak, and Yoseob Kim, and Hyunjeong Park, and Jae-Yong Jang, and Keun Kuk Lee, and Wonhui Yi, and Jeong-Ah Kwak, and Song-Gyu Park, and Hwanmook Kim, and Kiho Lee, and Jong Soon Kang, and Sang-Bae Han, and Bang Yeon Hwang, and Jin Tae Hong, and Jae-Kyung Jung, and Youngsoo Kim, and Jungsook Cho, and Heesoon Lee
January 2023, Anti-cancer agents in medicinal chemistry,
Copied contents to your clipboard!